GMA-106

N/A

Report date: 2025/01/03 14:50:15

Base Information

Drug NameGMA-106
Drug Alias Name重组人胰高糖素样肽1修饰抗人葡萄糖依赖性促胰岛素释放肽受体的人源化单克隆抗体GMA106GMA-106
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionGlucose-Dependent Insulinotropic Polypeptide Receptor antagonistsGlucagon-like peptide 1 receptor agonists
TargetsGlucagon-like peptide 1 receptorGlucose-Dependent Insulinotropic Polypeptide Receptor
Therapy Area/IndicationsOverweightObesity
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryAustraliaMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesGmax Biopharm Llc
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesSino Biopharmaceutical LtdGmax Biopharm Australia Pty LtdGmax Biopharm Llc
Inactive CompaniesN/A
Active IndicationsOverweightObesity
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A